

Factors Associated with Pain Reduction after Cryoneurolysis in Patients Undergoing TKA

Trevor Lee Toavs, Vijay Sudheendra, Thomas Barrett, Brandon Lentine

INTRODUCTION:

Preoperative cryoanalgesia is a non-opioid pain management technique for total knee arthroplasty (TKA). This study aimed to evaluate the efficacy of cryoanalgesia in reducing preoperative pain in patients with end stage knee OA prior to undergoing TKA.

METHODS:

A retrospective review of all patients undergoing cryoanalgesia prior to TKA at a single institution was performed. Only cases of primary TKA were included. Numeric rating scale (NRS) pain questionnaires were completed while at rest, during active range of motion (ROM), passive ROM, and while weight bearing both before and immediately after the administration of cryoanalgesia. Pre and post treatment pain scores were compared using paired tests. Multiple linear regression was used to assess the relationship between patient factors and change in NRS pain scores while controlling for pretreatment pain levels. The percentage of patients achieving the minimal clinically important difference (MCID), substantial clinical benefit (SCB), and patient acceptable symptom state (PASS) were determined using previously published values of 1, 2, and 3 or less, respectively.

RESULTS: 111 patients with a mean age of 68.7 ± 8.2 years and BMI of 32.3 ± 6.1 were included. Seventy-eight were female (70.3 percent) (Table 1). Females had greater pretreatment pain scores while at rest (5.2 ± 1.1 vs. 3.9 ± 2.5 , $p=.016$), with passive ROM (6.5 ± 2.3 vs. 5.3 ± 2.2 , $p=.008$), and with active ROM (7.7 ± 2.1 vs. 6.2 ± 2.6 , $p=.002$) (Table 2). There was a significant reduction in NRS pain scores after treatment with cryoanalgesia (at rest: 4.8 ± 2.5 vs. 1.0 ± 0.97 ; passive ROM: 6.2 ± 2.3 vs. 1.2 ± 1.2 ; active ROM: 7.2 ± 2.3 vs. 1.3 ± 1.2 ; weight bearing: 7.8 ± 2.4 vs. 1.2 ± 1.3 ; $p<.0001$ for all). On multiple regression analysis adjusted for pretreatment pain scores, no demographic factor was significantly associated with improvement in NRS pain (Table 3). MCID, SCB, and PASS were achieved by over 92%, 81%, and 95% of patients, respectively (Table 4). No complications occurred.

DISCUSSION AND CONCLUSION:

Cryoanalgesia is effective at reducing pain prior to TKA. The efficacy of cryoanalgesia was not influenced by patient demographics making it a suitable opioid sparing pain management strategy for a wide range of patients.

Table 1. Demographics of included patients

	Total cohort (n=111)	Males (n=33)	Females (n=78)	p-value
Age	68.7 (8.2)	68.5 (6.9)	69.4 (8.3)	0.897
BMI	32.3 (6.1)	32.2 (6.9)	32.3 (6.2)	0.93
ASA (%)				0.1
1	2 (1.8)	0 (0.0)	2 (2.6)	
2	54 (48.6)	21 (63.6)	33 (42.3)	
3	55 (49.6)	33 (100.0)	22 (28.1)	
Insurance (%)				0.39
Commercial	50 (45.0)	13 (39.4)	37 (47.4)	
Medicare	60 (54.0)	20 (60.6)	40 (51.6)	
Medicaid	1 (0.9)	1 (3.0)	0 (0.0)	

Mean reported in mean and standard deviation unless otherwise specified.

Table 2. Improvement in NRS Pain Scores after Cryoneurolysis by Gender

Pain	Pre		Post		p-value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
At rest	4.8 (2.5)	4.0 (2.0)	1.0 (0.97)	1.0 (0.97)	<.0001
Passive ROM	6.2 (2.3)	5.3 (2.2)	1.2 (1.2)	1.2 (1.2)	<.0001
Active ROM	7.2 (2.3)	6.2 (2.6)	1.3 (1.2)	1.3 (1.2)	<.0001
Weight bearing	7.8 (2.4)	7.8 (2.4)	1.2 (1.3)	1.2 (1.3)	<.0001

* p-value for comparison of post-treatment NRS pain scores pre-treatment scores by gender and females. ** comparison of pain change by gender and males and females.

Table 3. Factors associated with decrease in NRS pain scores

Factor	Univariable Linear Regression		Multiple-Linear Regression	
	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value
Female sex	1.03 (0.4, 1.6)	0.002	0.00	0.81
Age	-0.05 (-0.01, 0.1)	0.20	-0.05 (-0.01, 0.1)	0.20
BMI	-0.02 (-0.05, 0.01)	0.25	-0.02 (-0.05, 0.01)	0.25
Insurance	-0.01 (-0.14, 0.12)	0.92	-0.01 (-0.14, 0.12)	0.92
Passive				
Age	-0.05 (-0.1, 0.01)	0.06	-0.05 (-0.1, 0.01)	0.06
Female sex	1.22 (0.4, 2.0)	0.002	1.22 (0.4, 2.0)	0.002
BMI	-0.02 (-0.05, 0.01)	0.20	-0.02 (-0.05, 0.01)	0.20
ASA	-0.71 (-1.05, -0.37)	0.001	-0.71 (-1.05, -0.37)	0.001
Insurance	-0.01 (-0.15, 0.13)	0.92	-0.01 (-0.15, 0.13)	0.92
Active				
Age	-0.05 (-0.1, 0.01)	0.06	-0.05 (-0.1, 0.01)	0.06
Female sex	1.22 (0.4, 2.0)	0.002	1.22 (0.4, 2.0)	0.002
BMI	-0.02 (-0.05, 0.01)	0.20	-0.02 (-0.05, 0.01)	0.20
ASA	-0.71 (-1.05, -0.37)	0.001	-0.71 (-1.05, -0.37)	0.001
Insurance	-0.01 (-0.15, 0.13)	0.92	-0.01 (-0.15, 0.13)	0.92
Weight bearing				
Age	-0.06 (-0.1, 0.03)	0.12	-0.06 (-0.1, 0.03)	0.12
Female sex	1.32 (0.6, 2.0)	0.001	1.32 (0.6, 2.0)	0.001
BMI	0.01 (-0.02, 0.04)	0.66	0.01 (-0.02, 0.04)	0.66
ASA	-0.63 (-1.0, -0.26)	0.001	-0.63 (-1.0, -0.26)	0.001
Insurance	-0.01 (-0.15, 0.13)	0.92	-0.01 (-0.15, 0.13)	0.92

Results of univariable and multiple regression analyses. In regression analysis, ASA class 3 was compared to ASA class 2 and patients with Medicaid were compared to those with commercial insurance. Multiple regression analyses adjusted for pre-treatment NRS pain score for each factor.

Table 4. Percentage of patients achieving MCID, SCB, and PASS

Factor	MCID			SCB			PASS		
	Pre	Post	p-value	Pre	Post	p-value	Pre	Post	p-value
Female sex	92%	81%	0.001	92%	81%	0.001	95%	81%	0.001
Passive ROM	92%	81%	0.001	92%	81%	0.001	95%	81%	0.001
Active ROM	92%	81%	0.001	92%	81%	0.001	95%	81%	0.001
Weight bearing	92%	81%	0.001	92%	81%	0.001	95%	81%	0.001